Tax Rate: 14.23%
Is the tax rate high or low?
The tax rate of 14.23% is 49% above its 5-year average of 9.52%, near the high end of its 5-year range (-31.73%–23.47%).
10.09% below its 12-month average of 15.82%.
GSK Tax Rate
Reported quarterly effective tax rate; periods with non-meaningful pretax income are omitted.
GSK Average Tax Rate Chart
GSK Current vs Average Tax Rate Chart
GSK Tax Rate Metrics
TAX RATE
14.23%
TAX RATE AVG TTM
15.82%
TAX RATE AVG 3Y
13.38%
TAX RATE AVG 5Y
16.06%
TAX RATE AVG 10Y
15.12%
TAX RATE AVG 15Y
17.77%
TAX RATE AVG 20Y
20.58%
CURRENT VS TTM AVG
-10.09%
CURRENT VS 3Y AVG
+6.31%
CURRENT VS 5Y AVG
-11.42%
CURRENT VS 10Y AVG
-5.90%
CURRENT VS 15Y AVG
-19.93%
CURRENT VS 20Y AVG
-30.88%
Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tax Rate FAQ
- What is the tax rate for GSK plc (GSK)?
- The tax rate for GSK stock is 14.23%.
- Is GSK plc's tax rate high or low?
- The tax rate of 14.23% is 49% above its 5-year average of 9.52%, near the high end of its 5-year range (-31.73%–23.47%).
- What is the TTM average tax rate for GSK plc (GSK)?
- The TTM average tax rate for GSK stock is 15.82%.
- What is the 3Y average tax rate for GSK plc (GSK)?
- The 3Y average tax rate for GSK stock is 13.38%.
- What is the 5Y average tax rate for GSK plc (GSK)?
- The 5Y average tax rate for GSK stock is 16.06%.
- What is the 10Y average tax rate for GSK plc (GSK)?
- The 10Y average tax rate for GSK stock is 15.12%.
- What is the 15Y average tax rate for GSK plc (GSK)?
- The 15Y average tax rate for GSK stock is 17.77%.
- What is the 20Y average tax rate for GSK plc (GSK)?
- The 20Y average tax rate for GSK stock is 20.58%.
GSK Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2026-03-31 | 14.23% |
| 2025-12-31 | 23.47% |
| 2025-09-30 | 12.70% |
| 2025-06-30 | 12.77% |
| 2025-03-31 | 15.94% |
| 2024-12-31 | 11.01% |
| 2024-09-30 | -1.56% |
| 2024-06-30 | 12.78% |
| 2024-03-31 | 20.22% |
| 2023-12-31 | -5.01% |
| 2023-09-30 | 14.35% |
| 2023-06-30 | 12.18% |
| 2023-03-31 | 14.47% |
| 2022-12-31 | 0.06% |
| 2022-09-30 | 23.02% |
| 2022-06-30 | 16.74% |
| 2022-03-31 | 15.43% |
| 2021-12-31 | -31.73% |
| 2021-09-30 | 20.64% |
| 2021-06-30 | -18.79% |
| 2021-03-31 | 17.00% |
| 2020-12-31 | -2.19% |
| 2020-09-30 | 14.42% |
| 2020-06-30 | 7.61% |
| 2020-03-31 | 8.50% |
| 2019-12-31 | 11.34% |
| 2019-09-30 | 12.05% |
| 2019-06-30 | 16.93% |
| 2019-03-31 | 23.94% |
| 2018-12-31 | 5.39% |
| 2018-09-30 | 11.32% |
| 2018-06-30 | 22.64% |
| 2018-03-31 | 31.44% |
| 2017-12-31 | 182.13% |
| 2017-09-30 | 18.47% |
| 2017-03-31 | 21.10% |
| 2016-12-31 | 25.06% |
| 2016-09-30 | 30.53% |
| 2016-03-31 | 37.14% |
| 2015-09-30 | 25.37% |
| 2015-06-30 | 24.34% |
| 2015-03-31 | 19.00% |
| 2014-12-31 | -93.03% |
| 2014-09-30 | 29.74% |
| 2014-06-30 | 28.80% |
| 2014-03-31 | 20.38% |
| 2013-12-31 | 1.61% |
| 2013-09-30 | 27.96% |
| 2013-06-30 | 15.84% |
| 2013-03-31 | 27.07% |
| 2012-12-31 | 52.08% |
| 2012-09-30 | 20.71% |
| 2012-06-30 | 14.78% |
| 2012-03-31 | 26.02% |
| 2011-12-31 | 24.51% |
| 2011-09-30 | 25.66% |
| 2011-06-30 | 27.95% |
| 2011-03-31 | 35.71% |
| 2010-09-30 | 25.35% |
| 2010-03-31 | 27.76% |
| 2009-12-31 | 25.87% |
| 2009-09-30 | 28.33% |
| 2009-06-30 | 29.15% |
| 2009-03-31 | 29.83% |
| 2008-12-31 | 27.15% |
| 2008-09-30 | 32.00% |
| 2008-06-30 | 28.81% |
| 2008-03-31 | 28.92% |
| 2007-12-31 | 33.07% |
| 2007-09-30 | 28.47% |
| 2007-06-30 | 28.53% |
| 2007-03-31 | 28.46% |
| 2006-12-31 | 29.54% |
| 2006-09-30 | 29.48% |
| 2006-06-30 | 29.51% |
| 2006-03-31 | 29.49% |
| 2005-12-31 | 28.33% |
| 2005-09-30 | 28.52% |
| 2005-06-30 | 28.46% |
| 2005-03-31 | 28.52% |
| 2004-12-31 | 30.54% |
| 2004-09-30 | 31.71% |
| 2004-06-30 | 27.66% |
| 2004-03-31 | 27.69% |
| 2003-12-31 | 27.41% |
| 2003-09-30 | 27.37% |
| 2003-06-30 | 28.03% |
| 2003-03-31 | 27.00% |
| 2002-12-31 | 27.16% |
| 2002-09-30 | 26.04% |
| 2002-06-30 | 26.33% |
Related Metrics
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels